乳头液用于乳腺癌诊断的纳米孔Phi29 dna包装马达

IF 4.7 4区 医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Long Zhang PhD , Nicolas Burns BS , Zhouxiang Ji PhD , Steven Sun PhD , Susan L. Deutscher PhD , William E. Carson III MD , Peixuan Guo Ph.D. (Director of Center for Nanobiotechnology and Nanomedicine)
{"title":"乳头液用于乳腺癌诊断的纳米孔Phi29 dna包装马达","authors":"Long Zhang PhD ,&nbsp;Nicolas Burns BS ,&nbsp;Zhouxiang Ji PhD ,&nbsp;Steven Sun PhD ,&nbsp;Susan L. Deutscher PhD ,&nbsp;William E. Carson III MD ,&nbsp;Peixuan Guo Ph.D. (Director of Center for Nanobiotechnology and Nanomedicine)","doi":"10.1016/j.nano.2022.102642","DOIUrl":null,"url":null,"abstract":"<div><p>Detection of cancer in its early stage is a challenging task for oncologists. Inflammatory breast cancer has symptoms that are similar to mastitis and can be mistaken for microbial infection. Currently, the differential diagnosis between mastitis and Inflammatory breast cancer via nipple aspirate fluid (NAF) is difficult. Here, we report a label-free and amplification-free detection platform using an engineered nanopore of the phi29 DNA-packaging motor with biomarker Galectin3 (GAL3), Thomsen-Friedenreich (TF) binding peptide as the probe fused at its C-terminus. The binding of the biomarker in NAF samples from breast cancer patients to the probe results in the connector's conformational change with a current blockage of 32 %. Utilization of dwell time, blockage ratio, and peak signature enable us to detect basal levels of biomarkers from patient NAF samples at the single-molecule level. This platform will allow for breast cancers to be resolved at an early stage with accuracy and thoroughness.</p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":"48 ","pages":"Article 102642"},"PeriodicalIF":4.7000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035634/pdf/","citationCount":"2","resultStr":"{\"title\":\"Nipple fluid for breast cancer diagnosis using the nanopore of Phi29 DNA-packaging motor\",\"authors\":\"Long Zhang PhD ,&nbsp;Nicolas Burns BS ,&nbsp;Zhouxiang Ji PhD ,&nbsp;Steven Sun PhD ,&nbsp;Susan L. Deutscher PhD ,&nbsp;William E. Carson III MD ,&nbsp;Peixuan Guo Ph.D. (Director of Center for Nanobiotechnology and Nanomedicine)\",\"doi\":\"10.1016/j.nano.2022.102642\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Detection of cancer in its early stage is a challenging task for oncologists. Inflammatory breast cancer has symptoms that are similar to mastitis and can be mistaken for microbial infection. Currently, the differential diagnosis between mastitis and Inflammatory breast cancer via nipple aspirate fluid (NAF) is difficult. Here, we report a label-free and amplification-free detection platform using an engineered nanopore of the phi29 DNA-packaging motor with biomarker Galectin3 (GAL3), Thomsen-Friedenreich (TF) binding peptide as the probe fused at its C-terminus. The binding of the biomarker in NAF samples from breast cancer patients to the probe results in the connector's conformational change with a current blockage of 32 %. Utilization of dwell time, blockage ratio, and peak signature enable us to detect basal levels of biomarkers from patient NAF samples at the single-molecule level. This platform will allow for breast cancers to be resolved at an early stage with accuracy and thoroughness.</p></div>\",\"PeriodicalId\":396,\"journal\":{\"name\":\"Nanomedicine: Nanotechnology, Biology and Medicine\",\"volume\":\"48 \",\"pages\":\"Article 102642\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035634/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine: Nanotechnology, Biology and Medicine\",\"FirstCategoryId\":\"1\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1549963422001289\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine: Nanotechnology, Biology and Medicine","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963422001289","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 2

摘要

对肿瘤学家来说,早期发现癌症是一项具有挑战性的任务。炎症性乳腺癌的症状与乳腺炎相似,可能被误认为是微生物感染。目前,乳头抽吸液鉴别乳腺炎和炎性乳腺癌比较困难。在这里,我们报告了一个无标记和无扩增的检测平台,使用phi29 dna包装马达的工程纳米孔,生物标志物Galectin3 (GAL3), Thomsen-Friedenreich (TF)结合肽作为其c端融合的探针。来自乳腺癌患者的NAF样本中的生物标志物与探针的结合导致连接器的构象变化,电流阻塞为32%。利用停留时间、阻断比和峰值特征,我们能够在单分子水平上检测患者NAF样本中生物标志物的基础水平。这个平台将使乳腺癌在早期阶段得到准确和彻底的解决。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nipple fluid for breast cancer diagnosis using the nanopore of Phi29 DNA-packaging motor

Nipple fluid for breast cancer diagnosis using the nanopore of Phi29 DNA-packaging motor

Detection of cancer in its early stage is a challenging task for oncologists. Inflammatory breast cancer has symptoms that are similar to mastitis and can be mistaken for microbial infection. Currently, the differential diagnosis between mastitis and Inflammatory breast cancer via nipple aspirate fluid (NAF) is difficult. Here, we report a label-free and amplification-free detection platform using an engineered nanopore of the phi29 DNA-packaging motor with biomarker Galectin3 (GAL3), Thomsen-Friedenreich (TF) binding peptide as the probe fused at its C-terminus. The binding of the biomarker in NAF samples from breast cancer patients to the probe results in the connector's conformational change with a current blockage of 32 %. Utilization of dwell time, blockage ratio, and peak signature enable us to detect basal levels of biomarkers from patient NAF samples at the single-molecule level. This platform will allow for breast cancers to be resolved at an early stage with accuracy and thoroughness.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.10
自引率
3.60%
发文量
104
审稿时长
4.6 months
期刊介绍: Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信